Review
Published on 09 Feb 2023
PTCL, NOS: An update on classification, risk-stratification, and treatment
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1101441
- 16,739 views
- 19 citations
35 articles related to "Ptcl"
Articles
Systematic Review
Published on 13 Jun 2023
Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1127112
- 5,483 views
- 8 citations
Editorial
Published on 16 Sep 2022
Editorial: PTCL from genes to therapy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1014483
- 3,013 views
- 2 citations
Mini Review
Published on 26 Sep 2016
Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2016.00206
- 5,954 views
- 4 citations
Original Research
Published on 13 Oct 2020
Increased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2020.584261
- 6,456 views
- 13 citations
Review
Published on 24 Jan 2020
The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2020.00023
- 16,108 views
- 46 citations
Review
Published on 26 Apr 2022
Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2022.869488
- 12,561 views
- 22 citations
Original Research
Published on 15 May 2023
A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1162413
- 2,869 views
- 3 citations
Original Research
Published on 09 Mar 2023
A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1143556
- 3,112 views
- 3 citations
Review
Published on 26 Jan 2023
Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma
in Alloimmunity and Transplantation
Frontiers in Immunology
doi 10.3389/fimmu.2023.1068662
- 8,887 views
- 14 citations
Review
Published on 30 Aug 2023
Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1195759
- 6,447 views
- 1 citation
Original Research
Published on 12 May 2022
Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.874462
- 8,591 views
- 12 citations
Original Research
Published on 02 Feb 2022
Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2022.835103
- 5,115 views
- 30 citations
Review
Published on 23 Jun 2023
How molecular advances may improve the diagnosis and management of PTCL patients
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1202964
- 6,413 views
- 3 citations
Original Research
Published on 17 Nov 2022
Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1039888
- 3,300 views
- 3 citations
Original Research
Published on 04 Nov 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2021.750323
- 10,897 views
- 23 citations